VOR

Vor Biopharma Inc. (NASDAQ:VOR) is a clinical-stage biotechnology company founded in 2015 and headquartered in Cambridge, Massachusetts. The company went public in February 2021 through an initial public offering. Vor Biopharma specializes in developing engineered hematopoietic stem cell therapies designed to treat blood cancers, particularly acute myeloid leukemia and other hematological malignancies. The company represents an innovative approach in the biotechnology sector, focusing on genetically modifying patients' own stem cells to make them resistant to certain cancer treatments, thereby allowing for more aggressive therapeutic interventions.